{"protocolSection":{"identificationModule":{"nctId":"NCT00411749","orgStudyIdInfo":{"id":"V501-028"},"secondaryIdInfos":[{"id":"2006_052"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)","officialTitle":"V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years"},"statusModule":{"statusVerifiedDate":"2017-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-12-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2009-09-18","type":"ACTUAL"},"completionDateStruct":{"date":"2009-09-18","type":"ACTUAL"},"studyFirstSubmitDate":"2006-12-14","studyFirstSubmitQcDate":"2006-12-14","studyFirstPostDateStruct":{"date":"2006-12-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-07-19","resultsFirstSubmitQcDate":"2010-07-19","resultsFirstPostDateStruct":{"date":"2010-08-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-03-23","lastUpdatePostDateStruct":{"date":"2017-04-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females"},"conditionsModule":{"conditions":["HPV Infections"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":107,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"V501","type":"EXPERIMENTAL","description":"V501 vaccination Quadrivalent HPV (Types 6, 11, 16,\n\n18\\) L1 VLP Vaccine Injection\n\ncervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle \\[VLP\\] Type 6,\n\nType 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6.","interventionNames":["Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen","interventionNames":["Biological: Comparator: Placebo (unspecified)"]}],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)","description":"V501; Gardasil, 0.5 ml injection in 3 dosing regimen","armGroupLabels":["V501"],"otherNames":["V501","Gardasil"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo (unspecified)","description":"Placebo 0.5 ml injection in 3 dosing regimen","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Human Papilloma Virus (HPV) 6 Serum Antibody Titer at One Month After Completed Vaccination Series","description":"Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers (GMT) by vaccine group.\n\nThe limit of detection of the assay was 7 mMU/ml. GMTs and confidence limits below the limit of detection are shown as \"7.0\".","timeFrame":"At one month after completed vaccination series (Month 7)"},{"measure":"Human Papilloma Virus (HPV) 11 Serum Antibody Titer at One Month After Completed Vaccination Series","description":"Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.\n\nThe limit of detection of the assay was 8 mMU/ml. GMTs and confidence limits below the limit of detection are shown as \"8.0\".","timeFrame":"At one month after completed vaccination series (Month 7)"},{"measure":"Human Papilloma Virus (HPV) 16 Serum Antibody Titer at One Month After Completed Vaccination Series","description":"Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.\n\nThe limit of detection of the assay was 11 mMU/ml. GMTs and confidence limits below the limit of detection are shown as \"11.0\".","timeFrame":"At one month after completed vaccination series (Month 7)"},{"measure":"Human Papilloma Virus (HPV) 18 Serum Antibody Titer at One Month After Completed Vaccination Series","description":"Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.\n\nThe limit of detection of the assay was 10 mMU/ml. GMTs and confidence limits below the limit of detection are shown as \"10.0\".","timeFrame":"At one month after completed vaccination series (Month 7)"}],"secondaryOutcomes":[{"measure":"HPV 6, 11, 16 and 18 Serum Antibody Titer at 24 Month After Completed Vaccination Series","description":"Month 30 HPV cLIA Geometric Mean Titers by vaccine group.","timeFrame":"24 month after completed vaccination series (Month 30)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Virginal Female Subject Aged 9 To 17 Years\n\nExclusion Criteria:\n\n* Male Subject","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"9 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"32827835","type":"DERIVED","citation":"Murata S, Shirakawa M, Sugawara Y, Shuto M, Sawata M, Tanaka Y. Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants. Papillomavirus Res. 2020 Dec;10:100205. doi: 10.1016/j.pvr.2020.100205. Epub 2020 Aug 19."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final\\_Updated%20July\\_9\\_2014.pdf\n\nhttp://engagezone.msd.com/ds\\_documentation.php"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Study was conducted at 8 sites in Japan from 2006 to 2009.","groups":[{"id":"FG000","title":"V501","description":"V501 vaccination: Gardasil, 0.5 ml injection in 3 dosing regimen. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)"},{"id":"FG001","title":"Placebo","description":"Placebo vaccination 0.5 ml injection in 3 dosing regimen."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"25"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"25"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Completed at 24 month after vaccination series (Month 30). Subjects were followed until Month 30","numSubjects":"82"},{"groupId":"FG001","comment":"Completed at 1 month after vaccination series (Month 7). Subjects were followed until Month 7","numSubjects":"25"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"V501","description":"V501 vaccination: Gardasil, 0.5 ml injection in 3 dosing regimen. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)"},{"id":"BG001","title":"Placebo","description":"Placebo vaccination 0.5 ml injection in 3 dosing regimen."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"107"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12.8","spread":"2.4"},{"groupId":"BG001","value":"12.6","spread":"2.6"},{"groupId":"BG002","value":"12.7","spread":"2.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"107"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Body Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Kilogram","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45.5","spread":"10.8"},{"groupId":"BG001","value":"45.2","spread":"9.6"},{"groupId":"BG002","value":"45.4","spread":"10.5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Human Papilloma Virus (HPV) 6 Serum Antibody Titer at One Month After Completed Vaccination Series","description":"Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers (GMT) by vaccine group.\n\nThe limit of detection of the assay was 7 mMU/ml. GMTs and confidence limits below the limit of detection are shown as \"7.0\".","populationDescription":"The per protocol immunogenicity population includes all subjects who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and a Month 7 serum sample collected within an acceptable time range.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Titers (mMU/mL)","timeFrame":"At one month after completed vaccination series (Month 7)","groups":[{"id":"OG000","title":"V501","description":"V501 vaccination: Gardasil, 0.5 ml injection in 3 dosing regimen. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)"},{"id":"OG001","title":"Placebo","description":"Placebo vaccination 0.5 ml injection in 3 dosing regimen."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"674.5","lowerLimit":"528.6","upperLimit":"860.8"},{"groupId":"OG001","value":"7.0","lowerLimit":"7.0","upperLimit":"8.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Wilcoxon (Mann-Whitney)","ciPctValue":"95"}]},{"type":"PRIMARY","title":"Human Papilloma Virus (HPV) 11 Serum Antibody Titer at One Month After Completed Vaccination Series","description":"Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.\n\nThe limit of detection of the assay was 8 mMU/ml. GMTs and confidence limits below the limit of detection are shown as \"8.0\".","populationDescription":"The per protocol immunogenicity population includes all subjects who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and a Month 7 serum sample collected within an acceptable time range.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Titers (mMU/mL)","timeFrame":"At one month after completed vaccination series (Month 7)","groups":[{"id":"OG000","title":"V501","description":"V501 vaccination: Gardasil, 0.5 ml injection in 3 dosing regimen. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)"},{"id":"OG001","title":"Placebo","description":"Placebo vaccination 0.5 ml injection in 3 dosing regimen."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"944.5","lowerLimit":"755.3","upperLimit":"1181.0"},{"groupId":"OG001","value":"8.0","lowerLimit":"8.0","upperLimit":"8.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Wilcoxon (Mann-Whitney)","ciPctValue":"95"}]},{"type":"PRIMARY","title":"Human Papilloma Virus (HPV) 16 Serum Antibody Titer at One Month After Completed Vaccination Series","description":"Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.\n\nThe limit of detection of the assay was 11 mMU/ml. GMTs and confidence limits below the limit of detection are shown as \"11.0\".","populationDescription":"The per protocol immunogenicity population includes all subjects who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and a Month 7 serum sample collected within an acceptable time range.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Titers (mMU/mL)","timeFrame":"At one month after completed vaccination series (Month 7)","groups":[{"id":"OG000","title":"V501","description":"V501 vaccination: Gardasil, 0.5 ml injection in 3 dosing regimen. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)"},{"id":"OG001","title":"Placebo","description":"Placebo vaccination 0.5 ml injection in 3 dosing regimen."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4275.4","lowerLimit":"3375.4","upperLimit":"5415.4"},{"groupId":"OG001","value":"11.0","lowerLimit":"11.0","upperLimit":"13.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Wilcoxon (Mann-Whitney)","ciPctValue":"95"}]},{"type":"PRIMARY","title":"Human Papilloma Virus (HPV) 18 Serum Antibody Titer at One Month After Completed Vaccination Series","description":"Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.\n\nThe limit of detection of the assay was 10 mMU/ml. GMTs and confidence limits below the limit of detection are shown as \"10.0\".","populationDescription":"The per protocol immunogenicity population includes all subjects who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and a Month 7 serum sample collected within an acceptable time range.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Titers (mMU/mL)","timeFrame":"At one month after completed vaccination series (Month 7)","groups":[{"id":"OG000","title":"V501","description":"V501 vaccination: Gardasil, 0.5 ml injection in 3 dosing regimen. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)"},{"id":"OG001","title":"Placebo","description":"Placebo vaccination 0.5 ml injection in 3 dosing regimen."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"829.2","lowerLimit":"642.3","upperLimit":"1070.5"},{"groupId":"OG001","value":"10.0","lowerLimit":"10.0","upperLimit":"10.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Wilcoxon (Mann-Whitney)","ciPctValue":"95"}]},{"type":"SECONDARY","title":"HPV 6, 11, 16 and 18 Serum Antibody Titer at 24 Month After Completed Vaccination Series","description":"Month 30 HPV cLIA Geometric Mean Titers by vaccine group.","populationDescription":"The per protocol immunogenicity population includes all subjects who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and a Month 30 serum sample collected within an acceptable time range.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Titers (mMU/mL)","timeFrame":"24 month after completed vaccination series (Month 30)","groups":[{"id":"OG000","title":"V501-HPV 6","description":"HPV 6 serum antibody titer measured in V501 vaccination group"},{"id":"OG001","title":"V501-HPV 11","description":"HPV 11 serum antibody titer measured in V501 vaccination group"},{"id":"OG002","title":"V501-HPV 16","description":"HPV 16 serum antibody titer measured in V501 vaccination group"},{"id":"OG003","title":"V501-HPV 18","description":"HPV 18 serum antibody titer measured in V501 vaccination group"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"82"},{"groupId":"OG003","value":"82"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.2","lowerLimit":"126.2","upperLimit":"190.9"},{"groupId":"OG001","value":"198.2","lowerLimit":"160.9","upperLimit":"244.2"},{"groupId":"OG002","value":"617.1","lowerLimit":"491.7","upperLimit":"774.5"},{"groupId":"OG003","value":"90.0","lowerLimit":"68.8","upperLimit":"117.8"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Geometric Mean","paramValue":"155.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"126.2","ciUpperLimit":"190.9"},{"groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Geometric Mean","paramValue":"198.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"160.9","ciUpperLimit":"244.2"},{"groupIds":["OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Geometric Mean","paramValue":"617.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"491.7","ciUpperLimit":"774.5"},{"groupIds":["OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Geometric Mean","paramValue":"90.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"68.8","ciUpperLimit":"117.8"}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"Serious Adverse Event (SAE) data were collected from the entire period of the study. Other non serious AE data were collected from Day 1 to Day 15 following vaccination.","description":"All adverse events described in case report forms were tabulated by converting them to the preferred term (PT) and classifying them by primary system organ class (PSOC) using the International Conference on Harmonisation (ICH) medical dictionary for regulatory activities (MedDRA) Ver. 9.0.","eventGroups":[{"id":"EG000","title":"V501","description":"V501 vaccination: Gardasil, 0.5 ml injection in 3 dosing regimen. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)","seriousNumAffected":2,"seriousNumAtRisk":82,"otherNumAffected":77,"otherNumAtRisk":82},{"id":"EG001","title":"Placebo","description":"Placebo vaccination 0.5 ml injection in 3 dosing regimen.","seriousNumAffected":0,"seriousNumAtRisk":25,"otherNumAffected":23,"otherNumAtRisk":25}],"seriousEvents":[{"term":"Strabismus congenital","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":25}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":25}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":82},{"groupId":"EG001","numAffected":2,"numAtRisk":25}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":82},{"groupId":"EG001","numAffected":5,"numAtRisk":25}]},{"term":"Injection site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":25}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":69,"numAtRisk":82},{"groupId":"EG001","numAffected":19,"numAtRisk":25}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":25}]},{"term":"Malais","organSystem":"General disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":25}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":25}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":38,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":25}]},{"term":"Injection site discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":25}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":82},{"groupId":"EG001","numAffected":5,"numAtRisk":25}]},{"term":"Platelet count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":25}]},{"term":"Protein urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":82},{"groupId":"EG001","numAffected":2,"numAtRisk":25}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":25}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":25}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":82},{"groupId":"EG001","numAffected":2,"numAtRisk":25}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":25}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (9.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":25}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Japan"]},"conditionBrowseModule":{"meshes":[{"id":"D030361","term":"Papillomavirus Infections"}],"ancestors":[{"id":"D015229","term":"Sexually Transmitted Diseases, Viral"},{"id":"D012749","term":"Sexually Transmitted Diseases"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D014412","term":"Tumor Virus Infections"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D014614","term":"Vaccines, Synthetic"},{"id":"D000068857","term":"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18"}],"ancestors":[{"id":"D011994","term":"Recombinant Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D000941","term":"Antigens"},{"id":"D001685","term":"Biological Factors"},{"id":"D017778","term":"Vaccines, Combined"},{"id":"D053918","term":"Papillomavirus Vaccines"},{"id":"D014765","term":"Viral Vaccines"}]}},"hasResults":true}